Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Operating Margin (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Operating Margin for 16 consecutive years, with 15.46% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 647194.0% year-over-year to 15.46%, compared with a TTM value of 27.55% through Dec 2025, up 2506543.0%, and an annual FY2025 reading of 11.86%, up 1693892.0% over the prior year.
  • Operating Margin was 15.46% for Q4 2025 at Arrowhead Pharmaceuticals, down from 17.2% in the prior quarter.
  • Across five years, Operating Margin topped out at 70.24% in Q1 2025 and bottomed at 6456.48% in Q4 2024.
  • Average Operating Margin over 5 years is 774.72%, with a median of 169.49% recorded in 2021.
  • The sharpest move saw Operating Margin plummeted -377789bps in 2023, then skyrocketed 647194bps in 2025.
  • Year by year, Operating Margin stood at 230.77% in 2021, then surged by 71bps to 67.36% in 2022, then plummeted by -5608bps to 3845.25% in 2023, then plummeted by -68bps to 6456.48% in 2024, then soared by 100bps to 15.46% in 2025.
  • Business Quant data shows Operating Margin for ARWR at 15.46% in Q4 2025, 17.2% in Q3 2025, and 596.21% in Q2 2025.